NCT04115163 is a Phase 2 clinical trial of Gemcitabine in Metastatic Pancreatic Adenocarcinoma, sponsored by Anne Noonan.

Who is sponsoring NCT04115163?

NCT04115163 is sponsored by Anne Noonan.

What drugs are being tested in NCT04115163?

Interventions in NCT04115163: Gemcitabine, Nab-paclitaxel.

What condition does NCT04115163 study?

NCT04115163 studies Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8.

Is NCT04115163 still recruiting?

NCT04115163 is currently recruiting now. Last updated 11 February 2026.

Last reviewed 2026-02-11 · How we verify

NCT04115163

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Recruiting now Phase 2 Last updated 11 February 2026

What this trial tests

Phase 2 trial testing Gemcitabine in Metastatic Pancreatic Adenocarcinoma in 67 participants. Currently enrolling.

Timeline

24 June 2020

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	Anne Noonan
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	67
Start date	24 June 2020
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Gemcitabine (gemcitabine) — full drug profile →
Nab-paclitaxel (nab-paclitaxel) — full drug profile →

Conditions studied

Metastatic Pancreatic Adenocarcinoma — all drugs for Metastatic Pancreatic Adenocarcinoma →
Stage IV Pancreatic Cancer AJCC v8 — all drugs for Stage IV Pancreatic Cancer AJCC v8 →

Sponsor

Anne Noonan

Who can join

18 and older, any sex, with Metastatic Pancreatic Adenocarcinoma or Stage IV Pancreatic Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well a biologically optimized infusion schedule of gemcitabine and nab-paclitaxel works in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Altering the timing of the nab-paclitaxel infusion may improve response in patients with pancreatic cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Nanoparticle-based immunotherapy of pancreatic cancer.
Noubissi Nzeteu GA, Gibbs BF, Kotnik N, Troja A, et al · · 2022 · cited 14× · PMID 36106025 · DOI 10.3389/fmolb.2022.948898
Nanomedicine for cancer patient-centered care.
Sorrentino C, Ciummo SL, Fieni C, Di Carlo E. · · 2024 · cited 10× · PMID 39434967 · DOI 10.1002/mco2.767

Verify or expand the search:

Other trials of Gemcitabine

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting

Other recruiting trials for Metastatic Pancreatic Adenocarcinoma

Currently open trials in the same condition.

NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07226856 — BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent P · Phase 2 · recruiting
NCT07189195 — TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory · Phase 1 · recruiting
NCT06396091 — A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer · Phase 1 · active not recruiting
NCT06381154 — Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or · Phase 2 · recruiting

Other Anne Noonan trials

Trials by the same sponsor.

NCT04164069 — Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Recei · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04115163 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anne Noonan
Last refreshed: 11 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04115163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing